At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 189 enrolled
Drug / intervention
Durvalumab + Oleclumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
In Brief
A Phase 2 clinical trial evaluating Durvalumab + Oleclumab, Durvalumab, and 1 other intervention for Stage III Non-small Cell Lung Cancer and Unresectable. Completed, enrolled 189 participants across 73 sites in 9 countries.
Detailed Summary
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage III Non-small Cell Lung Cancer, Unresectable
CountriesCanada, France, Hong Kong, Italy, Poland, Portugal, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedJan 2019
Primary CompletionJul 2023
TodayJul 2026
First PostedJan 30, 2019
Enrollment StartDec 19, 2018
Primary CompletionJul 18, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 7.4 years ago
Interventions
Durvalumab + Oleclumabdrug
Durvalumab + Oleclumab
Durvalumabdrug
Durvalumab
Durvalumab + Monalizumabdrug
Durvalumab + Monalizumab